CASI Pharmaceuticals (NASDAQ:CASI – Get Rating) will post its quarterly earnings results before the market opens on Thursday, May 12th. Analysts expect CASI Pharmaceuticals to post earnings of ($0.10) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.
CASI Pharmaceuticals (NASDAQ:CASI – Get Rating) last announced its earnings results on Monday, March 28th. The biotechnology company reported ($0.04) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.02. CASI Pharmaceuticals had a negative net margin of 121.50% and a negative return on equity of 40.06%. During the same quarter in the previous year, the business earned ($0.12) earnings per share. On average, analysts expect CASI Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of CASI opened at $0.44 on Thursday. CASI Pharmaceuticals has a 12 month low of $0.40 and a 12 month high of $1.78. The firm has a fifty day simple moving average of $0.72 and a 200 day simple moving average of $0.82. The stock has a market capitalization of $60.51 million, a price-to-earnings ratio of -1.64 and a beta of 0.66.
A number of large investors have recently bought and sold shares of CASI. UBS Group AG boosted its position in CASI Pharmaceuticals by 493.1% during the 3rd quarter. UBS Group AG now owns 26,715 shares of the biotechnology company’s stock worth $32,000 after buying an additional 22,211 shares during the period. Citadel Advisors LLC acquired a new stake in CASI Pharmaceuticals during the 3rd quarter worth approximately $35,000. Virtu Financial LLC boosted its position in CASI Pharmaceuticals by 164.4% during the 4th quarter. Virtu Financial LLC now owns 80,806 shares of the biotechnology company’s stock worth $65,000 after buying an additional 50,246 shares during the period. Morgan Stanley boosted its position in CASI Pharmaceuticals by 781.2% during the 2nd quarter. Morgan Stanley now owns 43,285 shares of the biotechnology company’s stock worth $68,000 after buying an additional 38,373 shares during the period. Finally, Bank of America Corp DE boosted its position in CASI Pharmaceuticals by 111.1% during the 4th quarter. Bank of America Corp DE now owns 117,917 shares of the biotechnology company’s stock worth $94,000 after buying an additional 62,059 shares during the period. Institutional investors and hedge funds own 39.51% of the company’s stock.
CASI Pharmaceuticals Company Profile (Get Rating)
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
- Get a free copy of the StockNews.com research report on CASI Pharmaceuticals (CASI)
- High-Yield Weyco Group Returns To Reasonable Levels
- MarketBeat Podcast: Alternative Investing Strategies Despite Market Volatility
- Limelight Networks Stock is a Speculative Turnaround Opportunity
- The Selloff In SiteOne Landscape Supply Is Overextended
- Camping World Confirms Support At Institutional Bottom
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.